Abstract: The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

Abstract: The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

Abstract: Compounds for the treatment of cardiac insufficiency, an arterial thrombo embolism, an arterial occlusive disease, psoriasis, neurodermatitis, asthma, platelet aggregation and hypertension, of the formula ##STR1## in which R.sub.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl or C.sub.3-7 -cycloalkyl,R.sub.2 is hydrogen, C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl or C.sub.1-6 -hydroxyalkyl,R.sub.1 and R.sub.2 together with the carbon atom which carries them can be C.sub.3-7 -spiroalkyl,R.sub.3 is hydrogen or C.sub.1-6 -alkyl, andR.sub.4 is a cyanamido group, a 4-difluoromethoxy-3-pyridyl group or a C.sub.1-2 -nitroalkyl group, andZ is oxygen or sulphur,or a salt, acid addition salt, tautomer or optical isomer thereof.